Hands-On Training for Chinese Biotech Companies on Overseas Financing: NewCo Model Deep Dive – Suzhou, May 12-13, 2025
*Enrollment is now open. Register now to enjoyLimited-Time Early BirdTicket！
BiotechCompanies Are “Striding onto the Global Stage”!According to incomplete statistics, there were a total of 33 Chinese pharmaceutical overseas licensing deals in the first quarter of 2025, with disclosed amounts exceeding $36.2 billion.！In 2024, Hengrui, Keymed,Jiahui Bio, Anmab Biopharma, Virocell Biologics, and other pharmaceutical companies have successfully expanded overseas through the “NewCo” model. In the first quarter of 2025, Platinum Pharma,Kelun-BiotechPharmaceutical companies are also closely following the trend of “going global.” The wave of Chinese biotech firms expanding overseas is both a testament to technological breakthroughs and a microcosm of globalization dynamics. From license-out deals to the NewCo model, these companies consistently employ more flexible strategies to break through during the capital winter.
Going global is a tidal wave, but with “strong winds and high waves,” companies must make thorough preparations to “escort” their overseas expansion and cope withLack of systematic understanding of the entire cross-border financing process, frequent legal and intellectual property issues, misalignment between pipeline design and international clinical standards, and dual pressures from funding and policy environmentsand other core issues. To this end,VCBeatJointly with Button Capital, the series was launchedChinaPractical Training on Overseas Fundraising for Biotech Companies，On March 27 this year, the first session of 2025 was successfully held at the Haixing Pharmaceutical and Health Innovation Park in Haidian District, Beijing.FromEnd-to-End Practical Guide to Overseas Fundraising, Legal and Regulatory Risks, Taxation, and Intellectual Property,MNCSelection Criteria for Projects、Clinical Design StrategyEqual-angleBy sharing practical experience and conducting case analyses, we help biotech companies establish a faster and more stable foothold overseas, thereby achieving the internationalization of their products and technologies.
Reject Empty Talk, Focus on Practical Action!May 12–13, Suzhou · Bohe Innovation Center,VCBeat and Button Capital willEnableThe Second Practical Training on Overseas Financing for Chinese Biotech Companies in 2025!Cordially InvitedChina: Planning or Advancing Overseas FinancingBiotech Founders, CEOs, CFOs, and FinancingHeads and executives of strategic departments; FollowInvestors and Legal Advisors for Overseas Financing in BiotechParticipate!
1. Opportunities and Challenges for Biotech Companies in Overseas Financing (NewCo)
(1) Global Biotech Company Financing Overview
(2) Overseas Financing Activities of Chinese Biotech Companies
(3) Sharing of Success Cases Under the NewCo Innovation Model
(4) Opportunities and Challenges for Chinese Biotech Companies in Overseas Financing
2. Logical Architecture and End-to-End Practical Implementation of the NewCo Model
(1) Strategic Analysis of NewCo’s Global Expansion Model
(2) Building NewCo from 0 to 1: Strategic Logic and Architectural Design
(3) A Comprehensive Analysis of the Practical Implementation Process for the NewCo Model
3、Common Tax Considerations and Optimization for Cross-Border Transactions in Life Sciences Companies’ Global Expansion
4. How Chinese Biotech Companies Can Properly Avoid Pitfalls in BD-Driven Global Expansion and Going GlobalFinancing TransactionLegal Risks
(1) Common Forms of Overseas Financing Transactions for Chinese Biotech Companies (NewCo Model, BD Deals)
(2) Differences in the China-U.S. Agreement
(3) Legal Risks in Overseas Financing Transactions for Chinese Biotech Companies
(4) Interpretation of Practical Cases on How to Properly Avoid Legal Risks in International Transactions
5. How Chinese Biotech Companies Address Intellectual Property Issues in Cross-Border Transactions
(1) Forms of Intellectual Property Cooperation in Cross-Border Transactions for Chinese Biotech Companies
(2) Common Intellectual Property Issues in Cross-Border Transactions Involving Chinese Biotech Companies
(3) How Chinese Biotech Companies Can Maximize the Protection of Their Intellectual Property
(4) IP and Patent Challenge Strategies for Cross-Border Transactions of Chinese Biotech Companies
6、Sharing Experience in Global Business Operations for Enterprises in the Medical and Elderly Care Industry
(1) Establishment of Overseas Corporate Structure
(2) Overseas Account Selection
(3) Overseas Fund Management
(4) Cross-Border Financing Methods
（5）Overseas (Hong Kong, U.S.) Listing Strategy
7. Practical Insights from NewCo Operators
(1) How I Built NewCo
(2) Key Success Factors for NewCo
(3) How I Climbed Out of the Pitfalls I Encountered
8. Selection Criteria for Investment Projects of USD Funds
(1) Analysis of the Most Popular Sectors/Projects Among USD-Denominated Funds
(2) Specific Process and Criteria for Project Screening by USD Funds
（3）How to Negotiate Partnerships with U.S. Dollar Funds
9. Criteria and Direction for MNC Project Selection
(1) Analysis of the Current Investment Status and Directions of MNCs
(2) Specific Processes and Criteria for MNC Project Screening
(3) How to Negotiate Collaborations with MNCs
10. Clinical Strategies for Chinese Biotech Companies to Pursue Global Expansion
(1) What Kind of Clinical Data Is More Favored by Overseas Investors?
(2) Clinical Protocol Strategy and Design for International Projects
Scan the QR code to register
Secure Your Early Bird Spot
Scan the QR code to add Huimin from VCBeat
15111945514 (WeChat ID same as phone number)